{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:45:45Z","timestamp":1785732345280,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,2]]},"DOI":"10.7759\/cureus.113826","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:17:41Z","timestamp":1785730661000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum Uric Acid in Chronic Kidney Disease as a Marker of Risk or a Modifiable Driver of Progression: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Daniel E","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Sajjad Haider","family":"Gardezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawad","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allah Bux","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134567","article-title":"Cardiovascular risk and its presentation in chronic kidney disease","volume":"14","author":"Schunk SJ","year":"2025","unstructured":"Schunk SJ, Zimmermann P. Cardiovascular risk and its presentation in chronic kidney disease. J Clin Med. 2025, 14:10.3390\/jcm14134567","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102203","article-title":"Chronic kidney disease progression - a challenge","volume":"12","author":"Maringhini S","year":"2024","unstructured":"Maringhini S, Zoccali C. Chronic kidney disease progression - a challenge. Biomedicines. 2024, 12:10.3390\/biomedicines12102203","journal-title":"Biomedicines"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-023-00602-4","article-title":"The results of the URRAH (Uric Acid Right for Heart Health) project: a focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation","volume":"30","author":"Maloberti A","year":"2023","unstructured":"Maloberti A, Mengozzi A, Russo E, et al.. The results of the URRAH (Uric Acid Right for Heart Health) project: a focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation. High Blood Press Cardiovasc Prev. 2023, 30:411-25. 10.1007\/s40292-023-00602-4","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation","volume":"71","author":"Johnson RJ","year":"2018","unstructured":"Johnson RJ, Bakris GL, Borghi C, et al.. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018, 71:851-65. 10.1053\/j.ajkd.2017.12.009","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26189000","article-title":"Hyperuricemia in chronic kidney disease: emerging pathophysiology and a novel therapeutic strategy","volume":"26","author":"Takata T","year":"2025","unstructured":"Takata T, Mae Y, Hoi S, Iyama T, Isomoto H. Hyperuricemia in chronic kidney disease: emerging pathophysiology and a novel therapeutic strategy. Int J Mol Sci. 2025, 26:10.3390\/ijms26189000","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071771","article-title":"Association of uric acid with the decline in estimated glomerular filtration rate in middle-aged and elderly populations: evidence based on the China Health and Retirement Longitudinal Study","volume":"13","author":"Liu P","year":"2023","unstructured":"Liu P, Liang Y, Cui S, Hu K, Lin L, Shao X, Lei M. Association of uric acid with the decline in estimated glomerular filtration rate in middle-aged and elderly populations: evidence based on the China Health and Retirement Longitudinal Study. BMJ Open. 2023, 13:10.1136\/bmjopen-2023-071771","journal-title":"BMJ Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9101341","article-title":"Serum uric acid levels and risk of rapid decline of estimated glomerular filtration rate in patients with type 2 diabetes: findings from a 5-year prospective cohort study","volume":"9","author":"Le HT","year":"2021","unstructured":"Le HT, Le TT, Tran NM, et al.. Serum uric acid levels and risk of rapid decline of estimated glomerular filtration rate in patients with type 2 diabetes: findings from a 5-year prospective cohort study. Healthcare (Basel). 2021, 9:10.3390\/healthcare9101341","journal-title":"Healthcare (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-021-00204-4","article-title":"Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis","volume":"5","author":"Robinson PC","year":"2021","unstructured":"Robinson PC, Frampton C, Phipps-Green A, et al.. Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis. BMC Rheumatol. 2021, 5:10.1186\/s41927-021-00204-4","journal-title":"BMC Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi SA","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons. Health Sci Rep. 2024, 7:10.1002\/hsr2.2165","journal-title":"Health Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden JA","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013, 158:280-6. 10.7326\/0003-4819-158-4-201302190-00009","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-019-01840-4","article-title":"The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial","volume":"24","author":"Kuwabara Y","year":"2020","unstructured":"Kuwabara Y, Yasuno S, Kasahara M, Ueshima K, Nakao K. The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial. Clin Exp Nephrol. 2020, 24:420-6. 10.1007\/s10157-019-01840-4","journal-title":"Clin Exp Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae203","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial","volume":"40","author":"Mayne KJ","year":"2025","unstructured":"Mayne KJ, Sardell RJ, Staplin N, et al.. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2025, 40:720-30. 10.1093\/ndt\/gfae203","journal-title":"Nephrol Dial Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-019-01829-z","article-title":"Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia","volume":"24","author":"Matsuo H","year":"2020","unstructured":"Matsuo H, Ishikawa E, Machida H, et al.. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol. 2020, 24:307-13. 10.1007\/s10157-019-01829-z","journal-title":"Clin Exp Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.10.022","article-title":"Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy","volume":"107","author":"Ghang B","year":"2025","unstructured":"Ghang B, Park J, Lee JS, et al.. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney Int. 2025, 107:521-9. 10.1016\/j.kint.2024.10.022","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000326","article-title":"Combination treatment with verinurad and allopurinol in CKD: a randomized placebo and active controlled trial","volume":"35","author":"Heerspink HJ","year":"2024","unstructured":"Heerspink HJ, Stack AG, Terkeltaub R, et al..  Combination treatment with verinurad and allopurinol in CKD: a randomized placebo and active controlled trial. J Am Soc Nephrol. 2024, 35:594-606. 10.1681\/ASN.0000000000000326","journal-title":"J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria A","year":"2020","unstructured":"Doria A, Galecki AT, Spino C, et al.. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020, 382:2493-503. 10.1056\/NEJMoa1916624","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve SV","year":"2020","unstructured":"Badve SV, Pascoe EM, Tiku A, et al.. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020, 382:2504-13. 10.1056\/NEJMoa1915833","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.713652","article-title":"Serum uric acid and kidney disease measures independently predict cardiovascular and total mortality: the Uric Acid Right for Heart Health (URRAH) project","volume":"8","author":"Russo E","year":"2021","unstructured":"Russo E, Viazzi F, Pontremoli R, et al.. Serum uric acid and kidney disease measures independently predict cardiovascular and total mortality: the Uric Acid Right for Heart Health (URRAH) project. Front Cardiovasc Med. 2021, 8:10.3389\/fcvm.2021.713652","journal-title":"Front Cardiovasc Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051360","article-title":"The uricosuric effect of SGLT2 inhibitors is maintained in the long term in patients with chronic kidney disease and type 2 diabetes mellitus","volume":"13","author":"S\u00e1nchez-Briales P","year":"2024","unstructured":"S\u00e1nchez-Briales P, Vidas MM, L\u00f3pez-S\u00e1nchez P, L\u00f3pez-Ill\u00e1zquez MV, Mart\u00edn-Testillano L, Vedat-Ali A, Portol\u00e9s J. The uricosuric effect of SGLT2 inhibitors is maintained in the long term in patients with chronic kidney disease and type 2 diabetes mellitus. J Clin Med. 2024, 13:10.3390\/jcm13051360","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002725","article-title":"No causal effects of serum urate levels on the risk of chronic kidney disease: a Mendelian randomization study","volume":"16","author":"Jordan DM","year":"2019","unstructured":"Jordan DM, Choi HK, Verbanck M, et al.. No causal effects of serum urate levels on the risk of chronic kidney disease: a Mendelian randomization study. PLoS Med. 2019, 16:10.1371\/journal.pmed.1002725","journal-title":"PLoS Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503091-serum-uric-acid-in-chronic-kidney-disease-as-a-marker-of-risk-or-a-modifiable-driver-of-progression-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:17:45Z","timestamp":1785730665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503091-serum-uric-acid-in-chronic-kidney-disease-as-a-marker-of-risk-or-a-modifiable-driver-of-progression-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.113826","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}